Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 26.78 CHF 1.21%
Market Cap: CHf1B

Operating Margin

-1.7%
Current
Improving
by 24.7%
vs 3-y average of -26.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1.7%
=
Operating Income
CHf-2.1m
/
Revenue
CHf118.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1.7%
=
Operating Income
CHf-2.1m
/
Revenue
CHf118.4m

Peer Comparison

Country Company Market Cap Operating
Margin
CH
Kuros Biosciences AG
SIX:KURN
1B CHF
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 85% of companies in Switzerland
Percentile
15th
Based on 1 083 companies
15th percentile
-1.7%
Low
-62 472.2% — 3.5%
Typical Range
3.5% — 16.5%
High
16.5% — 91.2%
Distribution Statistics
Switzerland
Min -62 472.2%
30th Percentile 3.5%
Median 10.3%
70th Percentile 16.5%
Max 91.2%

Kuros Biosciences AG
Glance View

Market Cap
1B CHF
Industry
Biotechnology

Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

KURN Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1.7%
=
Operating Income
CHf-2.1m
/
Revenue
CHf118.4m
What is Kuros Biosciences AG's current Operating Margin?

The current Operating Margin for Kuros Biosciences AG is -1.7%, which is above its 3-year median of -26.4%.

How has Operating Margin changed over time?

Over the last 3 years, Kuros Biosciences AG’s Operating Margin has increased from -64% to -1.7%. During this period, it reached a low of -76.4% on Jun 30, 2023 and a high of 0.1% on Dec 31, 2024.

Back to Top